Stępniak, J.; Krawczyk-Lipiec, J.; Lewiński, A.; Karbownik-Lewińska, M.
Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid. Biomedicines 2022, 10, 2890.
https://doi.org/10.3390/biomedicines10112890
AMA Style
Stępniak J, Krawczyk-Lipiec J, Lewiński A, Karbownik-Lewińska M.
Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid. Biomedicines. 2022; 10(11):2890.
https://doi.org/10.3390/biomedicines10112890
Chicago/Turabian Style
Stępniak, Jan, Joanna Krawczyk-Lipiec, Andrzej Lewiński, and Małgorzata Karbownik-Lewińska.
2022. "Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid" Biomedicines 10, no. 11: 2890.
https://doi.org/10.3390/biomedicines10112890
APA Style
Stępniak, J., Krawczyk-Lipiec, J., Lewiński, A., & Karbownik-Lewińska, M.
(2022). Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid. Biomedicines, 10(11), 2890.
https://doi.org/10.3390/biomedicines10112890
